$16.7 Billion is the total value of Baker Brothers Advisors's 113 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Seagen Inc. | $6,028,695,304 | -6.1% | 46,912,266 | 0.0% | 36.20% | -13.9% | |
| BGNE | BeiGene, Ltd.sponsored adr | $2,566,457,206 | +63.1% | 11,668,897 | 0.0% | 15.41% | +49.6% | |
| BMRN | BioMarin Pharmaceutical Inc. | $788,644,924 | +22.1% | 7,620,494 | 0.0% | 4.74% | +11.9% | |
| ACAD | ACADIA Pharmaceuticals Inc. | $667,421,897 | -2.7% | 41,923,486 | 0.0% | 4.01% | -10.8% | |
| BCRX | BioCryst Pharmaceuticals, Inc. | $145,920,191 | -8.9% | 12,710,818 | 0.0% | 0.88% | -16.5% | |
| IMCR | Immunocore Holdings plcads | $143,858,118 | +21.6% | 2,520,731 | 0.0% | 0.86% | +11.5% | |
| AKRO | Akero Therapeutics, Inc. | $129,787,114 | +60.9% | 2,368,378 | 0.0% | 0.78% | +47.5% | |
| KOD | Kodiak Sciences Inc. | $123,943,108 | -7.5% | 17,310,490 | 0.0% | 0.74% | -15.2% | |
| HZNP | Horizon Therapeutics Public Ltd Co | $110,354,933 | +83.9% | 969,727 | 0.0% | 0.66% | +68.7% | |
| ARGX | argenx SEsponsored adr | $106,132,634 | +7.3% | 280,159 | 0.0% | 0.64% | -1.7% | |
| ABCL | AbCellera Biologics Inc. | $105,860,323 | +2.4% | 10,450,180 | 0.0% | 0.64% | -6.1% | |
| KYMR | Kymera Therapeutics, Inc. | $71,880,432 | +14.7% | 2,879,825 | 0.0% | 0.43% | +5.1% | |
| KDNY | Chinook Therapeutics, Inc. | $66,393,472 | +33.3% | 2,534,102 | 0.0% | 0.40% | +22.4% | |
| Entrada Therapeutics, Inc. | $65,785,873 | -14.2% | 4,865,819 | 0.0% | 0.40% | -21.3% | ||
| MRTX | Mirati Therapeutics, Inc. | $63,877,313 | -35.1% | 1,409,784 | 0.0% | 0.38% | -40.5% | |
| PRLD | Prelude Therapeutics Inc. | $61,147,897 | -8.6% | 10,123,824 | 0.0% | 0.37% | -16.2% | |
| CERS | Cerus Corporation | $58,646,587 | +1.4% | 16,067,558 | 0.0% | 0.35% | -7.1% | |
| IGMS | IGM Biosciences, Inc. | $53,685,295 | -25.2% | 3,156,102 | 0.0% | 0.32% | -31.5% | |
| NRIX | Nurix Therapeutics, Inc. | $42,625,733 | -15.7% | 3,882,125 | 0.0% | 0.26% | -22.7% | |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | $41,937,663 | +16.7% | 2,799,577 | 0.0% | 0.25% | +7.2% | |
| IDYA | IDEAYA Biosciences, Inc. | $30,314,010 | +21.8% | 1,668,355 | 0.0% | 0.18% | +11.7% | |
| XENE | Xenon Pharmaceuticals Inc. | $29,637,126 | +9.2% | 751,639 | 0.0% | 0.18% | 0.0% | |
| VERV | Verve Therapeutics, Inc. | $27,409,856 | -43.7% | 1,416,530 | 0.0% | 0.16% | -48.3% | |
| BCYC | Bicycle Therapeutics plcsponsored ads | $24,976,894 | +27.3% | 843,814 | 0.0% | 0.15% | +16.3% | |
| DBVT | DBV Technologies S.A.sponsored adr | $22,359,824 | -13.6% | 14,614,264 | 0.0% | 0.13% | -20.7% | |
| RARE | Ultragenyx Pharmaceutical Inc. | $21,820,225 | +11.9% | 470,974 | 0.0% | 0.13% | +2.3% | |
| HRTX | Heron Therapeutics, Inc. | $20,329,195 | -40.8% | 8,131,678 | 0.0% | 0.12% | -45.8% | |
| 2seventy bio, Inc. | $19,327,911 | -35.6% | 2,062,744 | 0.0% | 0.12% | -41.1% | ||
| BMEA | Biomea Fusion, Inc. | $17,741,432 | -13.8% | 2,104,559 | 0.0% | 0.11% | -20.7% | |
| BLUE | bluebird bio, Inc. | $17,298,028 | +9.3% | 2,499,715 | 0.0% | 0.10% | 0.0% | |
| NVTA | Invitae Corporation | $15,627,785 | -24.4% | 8,402,035 | 0.0% | 0.09% | -30.4% | |
| OPT | Opthea Limitedsponsored ads | $14,425,856 | -13.6% | 2,691,391 | 0.0% | 0.09% | -20.2% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $14,353,080 | +35.8% | 9,830,877 | 0.0% | 0.09% | +24.6% | |
| CBAY | CymaBay Therapeutics, Inc. | $13,608,809 | +79.1% | 2,170,464 | 0.0% | 0.08% | +64.0% | |
| Aadi Bioscience, Inc. | $12,700,776 | -9.2% | 989,928 | 0.0% | 0.08% | -17.4% | ||
| VSTM | Verastem, Inc. | $10,863,032 | -52.6% | 26,988,898 | 0.0% | 0.06% | -56.7% | |
| CinCor Pharma, Inc. | $9,920,635 | -62.6% | 807,212 | 0.0% | 0.06% | -65.5% | ||
| VOR | Vor Biopharma Inc. | $9,748,401 | +67.1% | 1,465,925 | 0.0% | 0.06% | +55.3% | |
| PACB | Pacific Biosciences of California, Inc. | $9,225,257 | +40.9% | 1,127,782 | 0.0% | 0.06% | +27.9% | |
| RETA | Reata Pharmaceuticals, Inc.cl a | $8,508,848 | +51.2% | 223,976 | 0.0% | 0.05% | +37.8% | |
| VERU | Veru Inc. | $8,498,577 | -54.2% | 1,609,579 | 0.0% | 0.05% | -57.9% | |
| PNT | POINT Biopharma Global Inc. | $8,522,761 | -5.7% | 1,169,103 | 0.0% | 0.05% | -13.6% | |
| AFMD | Affimed N.V. | $8,180,069 | -39.8% | 6,596,830 | 0.0% | 0.05% | -44.9% | |
| Invitae Corporationnote 2.0% 9/1/2024 | $8,058,143 | -1.1% | 10,300,000 | 0.0% | 0.05% | -9.4% | ||
| VERA | Vera Therapeutics, Inc.cl a | $6,449,994 | -9.2% | 333,333 | 0.0% | 0.04% | -17.0% | |
| MGNX | MacroGenics, Inc. | $5,989,205 | +94.0% | 892,579 | 0.0% | 0.04% | +80.0% | |
| Tango Therapeutics, Inc. | $5,437,500 | +100.3% | 750,000 | 0.0% | 0.03% | +83.3% | ||
| RVMD | Revolution Medicines, Inc. | $5,293,328 | +20.8% | 222,222 | 0.0% | 0.03% | +10.3% | |
| EWTX | Edgewise Therapeutics, Inc. | $4,470,000 | -9.1% | 500,000 | 0.0% | 0.03% | -15.6% | |
| TScan Therapeutics, Inc. | $4,316,428 | -49.2% | 2,784,792 | 0.0% | 0.03% | -53.6% | ||
| NTRA | Natera, Inc. | $4,017,000 | -8.3% | 100,000 | 0.0% | 0.02% | -17.2% | |
| TLIS | Talis Biomedical Corporation | $3,398,389 | -34.6% | 7,624,835 | 0.0% | 0.02% | -41.2% | |
| ITOS | iTeos Therapeutics, Inc. | $2,936,257 | +2.5% | 150,346 | 0.0% | 0.02% | -5.3% | |
| PMVP | PMV Pharmaceuticals, Inc. | $2,801,609 | -26.9% | 322,024 | 0.0% | 0.02% | -32.0% | |
| BCEL | Atreca, Inc. | $2,828,328 | -49.0% | 3,532,760 | 0.0% | 0.02% | -52.8% | |
| ATRA | Atara Biotherapeutics, Inc. | $2,440,930 | -13.2% | 744,186 | 0.0% | 0.02% | -16.7% | |
| ACHL | Achilles Therapeutics plcsponsored ads | $2,332,229 | -60.2% | 2,591,366 | 0.0% | 0.01% | -63.2% | |
| NKTX | Nkarta, Inc. | $2,396,000 | -54.5% | 400,000 | 0.0% | 0.01% | -58.8% | |
| FATE | Fate Therapeutics, Inc. | $2,176,363 | -55.0% | 215,695 | 0.0% | 0.01% | -59.4% | |
| NLTX | Neoleukin Therapeutics, Inc. | $1,945,266 | -20.5% | 3,821,740 | 0.0% | 0.01% | -25.0% | |
| ALGS | Aligos Therapeutics, Inc. | $1,978,602 | -13.4% | 2,076,400 | 0.0% | 0.01% | -20.0% | |
| AGLE | Aeglea BioTherapeutics, Inc. | $1,534,207 | -14.5% | 3,410,106 | 0.0% | 0.01% | -25.0% | |
| TCRR | TCR2 Therapeutics Inc. | $752,160 | -44.5% | 753,064 | 0.0% | 0.01% | -44.4% | |
| TARA | Protara Therapeutics, Inc. | $535,118 | -9.5% | 199,671 | 0.0% | 0.00% | -25.0% | |
| KZR | Kezar Life Sciences, Inc. | $436,100 | -18.2% | 61,946 | 0.0% | 0.00% | 0.0% | |
| GTH | Genetron Holdings Limitedads | $509,943 | +43.2% | 455,306 | 0.0% | 0.00% | +50.0% | |
| Sera Prognostics, Inc. | $253,968 | -21.1% | 201,562 | 0.0% | 0.00% | 0.0% | ||
| FHTX | Foghorn Therapeutics Inc. | $287,272 | -25.6% | 45,027 | 0.0% | 0.00% | -33.3% | |
| LPTX | Leap Therapeutics, Inc. | $251,867 | -48.9% | 559,705 | 0.0% | 0.00% | -33.3% | |
| INSM | Insmed Incorporated | $398,601 | -7.3% | 19,950 | 0.0% | 0.00% | -33.3% | |
| VINC | Vincerx Pharma, Inc. | $246,207 | -26.1% | 241,379 | 0.0% | 0.00% | -50.0% | |
| Bellicum Pharmaceuticals, Inc. | $179,369 | -40.0% | 249,123 | 0.0% | 0.00% | -50.0% | ||
| Surrozen, Inc.w exp 8/11/2026 | $45,917 | -70.2% | 833,333 | 0.0% | 0.00% | -100.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
| 4 | 2024-03-28 |
| SC 13D/A | 2024-03-28 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-14 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.